Skip to main content
SpringerLink
Log in

Components of the Plasminogen-Plasmin System as Biologic Markers for Cancer

  • Chapter
Advances in Cancer Biomarkers

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 867))

Abstract

Members of the plasminogen-plasmin (PP) system participate in many physiologic functions. In particular, uPA, its receptor (uPAR) and its inhibitor PAI-1 play an important role in cell migration, cell proliferation and tissue remodeling. Through a number of interactions, these components of the PP system are also involved in the pathogenesis of many diseases. In cancer, they modulate the essential processes of tumor development, growth, invasion and metastasis as well as angiogenesis and fibrosis. Thus, quantification of uPA, uPAR and PAI-1 in tumors and, in some cases in the circulating blood, became of potential value in the prognostication of many types of cancer. These include cancer of the breast, stomach, colon and rectum, esophagus, pancreas, glioma, lung, kidney, prostate, uterine cervix, ovary, liver and bone. Published data are reviewed in this chapter. Clinical validation of the prognostic value has also been made, particularly in cancer of the breast. Inclusion of these biomarkers in the risk assessment of cancer patients is now considered in the risk-adapted management in carcinoma of the breast. Factors limiting its broader use are discussed with suggestions how these can be overcome. Hopefully the use of these biomarkers will be applied to other types of cancer in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kwaan HC (1992) The biologic role of components of the plasminogen-plasmin system. Prog Cardiovasc Dis 34(5):309–316

    Article  CAS  PubMed  Google Scholar 

  2. Castellino FJ, Ploplis VA (2005) Structure and function of the plasminogen/plasmin system. Thromb Haemost 93(4):647–654

    CAS  PubMed  Google Scholar 

  3. Rijken DC, Lijnen HR (2009) New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 7(1):4–13

    Article  CAS  PubMed  Google Scholar 

  4. Declerck PJ, Gils A (2013) Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. Semin Thromb Hemost 39(4):356–364, Mar 26, epub ahead of print

    Article  CAS  PubMed  Google Scholar 

  5. Vercauteren E, Gils A, Declerck PJ (2013) Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis. Semin Thromb Hemost 39(4):365–372, Mar 26, epub ahead of print

    Article  CAS  PubMed  Google Scholar 

  6. Bouton MC, Boulaftali Y, Richard B, Arocas V, Michel JB, Jandrot-Perrus M (2012) Emerging role of serpinE2/protease nexin-1 in hemostasis and vascular biology. Blood 119(11):2452–2457

    Article  CAS  PubMed  Google Scholar 

  7. Ferraris GM, Sidenius N (2013) Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction. Semin Thromb Hemost 39(4):347–355

    Article  CAS  PubMed  Google Scholar 

  8. Miles LA, Parmer RJ (2013) Plasminogen receptors: the first quarter century. Semin Thromb Hemost 39(4):329–337

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Binder BR, Mihaly J, Prager GW (2007) uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist’s view. Thromb Haemost 97(3):336–342

    CAS  PubMed  Google Scholar 

  10. Pepper MS (2001) Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21(7):1104–1117

    Article  CAS  PubMed  Google Scholar 

  11. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57(1):25–40

    Article  CAS  PubMed  Google Scholar 

  12. Kwaan HC (1992) The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11(3–4):291–311

    Article  CAS  PubMed  Google Scholar 

  13. Dano K, Behrendt N, Hoyer-Hansen G et al (2005) Plasminogen activation and cancer. Thromb Haemost 93(4):676–681

    CAS  PubMed  Google Scholar 

  14. Kwaan HC, McMahon B (2009) The role of plasminogen-plasmin system in cancer. Cancer Treat Res 148:43–66

    Article  CAS  PubMed  Google Scholar 

  15. Deryugina EI, Quigley JP (2012) Cell surface remodeling by plasmin: a new function for an old enzyme. J Biomed Biotechnol 2012:564259

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  16. Carroll VA, Binder BR (1999) The role of the plasminogen activation system in cancer. Semin Thromb Hemost 25(2):183–197

    Article  CAS  PubMed  Google Scholar 

  17. Billroth T (1878) Lectures on surgical pathology and therapeutics. A handbook for students and practitioners. The New Sydenham Society, London

    Google Scholar 

  18. Carrel A, Burrows MT (1911) Cultivation in vitro of malignant tumors. J Exp Med 13(5):571–575

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Tagnon HJ, Whitmore WF Jr, Schulman P, Kravitz SC (1953) The significance of fibrinolysis occurring in patients with metastatic cancer of the prostate. Cancer 6(1):63–67

    Article  CAS  PubMed  Google Scholar 

  20. Ossowski L, Quigley JP, Kellerman GM, Reich E (1973) Fibrinolysis associated with oncogenic transformation. Requirement of plasminogen for correlated changes in cellular morphology, colony formation in agar, and cell migration. J Exp Med 138(5):1056–1064

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Astedt B, Holmberg L (1976) Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 261(5561):595–597

    Article  CAS  PubMed  Google Scholar 

  22. Kwaan HC, Mazar AP, McMahon BJ (2013) The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost 39(4):382–391, Mar 26, epub ahead of print

    Article  CAS  PubMed  Google Scholar 

  23. Look MP, van Putten WL, Duffy MJ et al (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94(2):116–128

    Article  CAS  PubMed  Google Scholar 

  24. Janicke F, Prechtl A, Thomssen C et al (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93(12):913–920

    Article  CAS  PubMed  Google Scholar 

  25. Duffy MJ, Duggan C, Mulcahy HE, McDermott EW, O’Higgins NJ (1998) Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 44(6 Pt 1):1177–1183

    CAS  PubMed  Google Scholar 

  26. Grondahl-Hansen J, Peters HA, van Putten WL et al (1995) Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1(10):1079–1087

    CAS  PubMed  Google Scholar 

  27. Sternlicht MD, Dunning AM, Moore DH et al (2006) Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev 15(11):2107–2114

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Foekens JA, Buessecker F, Peters HA et al (1995) Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55(7):1423–1427

    CAS  PubMed  Google Scholar 

  29. Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG (1995) Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87(10):751–756

    Article  CAS  PubMed  Google Scholar 

  30. Harbeck N, Kates RE, Look MP et al (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 62(16):4617–4622

    CAS  PubMed  Google Scholar 

  31. Harbeck N, Kates RE, Schmitt M (2002) Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 20(4):1000–1007

    Article  PubMed  Google Scholar 

  32. Harbeck N, Kates RE, Schmitt M et al (2004) Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5(5):348–352

    Article  CAS  PubMed  Google Scholar 

  33. Ji F, Chen YL, Jin EY, Wang WL, Yang ZL, Li YM (2005) Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer. World J Gastroenterol 11(21):3222–3226

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Heiss MM, Babic R, Allgayer H et al (1995) Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 13(8):2084–2093

    CAS  PubMed  Google Scholar 

  35. Nekarda H, Schmitt M, Ulm K et al (1994) Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54(11):2900–2907

    CAS  PubMed  Google Scholar 

  36. Zhang L, Zhao ZS, Ru GQ, Ma J (2006) Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World J Gastroenterol 12(25):3970–3976

    PubMed Central  CAS  PubMed  Google Scholar 

  37. Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS (1997) High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer 79(5):878–883

    Article  CAS  PubMed  Google Scholar 

  38. Stephens RW, Nielsen HJ, Christensen IJ et al (1999) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91(10):869–874

    Article  CAS  PubMed  Google Scholar 

  39. Riisbro R, Christensen IJ, Nielsen HJ, Brunner N, Nilbert M, Fernebro E (2005) Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-receptor and biomarker group collaboration. Int J Biol Markers 20(2):93–102

    CAS  PubMed  Google Scholar 

  40. Skelly MM, Troy A, Duffy MJ et al (1997) Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res 3(10):1837–1840

    CAS  PubMed  Google Scholar 

  41. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW (1994) Urokinase receptor and colorectal cancer survival. Lancet 344(8919):401–402

    Article  CAS  PubMed  Google Scholar 

  42. Torzewski M, Sarbia M, Verreet P et al (1997) Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus. Clin Cancer Res 3(12 Pt 1):2263–2268

    CAS  PubMed  Google Scholar 

  43. Nekarda H, Schlegel P, Schmitt M et al (1998) Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res 4(7):1755–1763

    CAS  PubMed  Google Scholar 

  44. Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T (2000) Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 156(2):567–575

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Hsu DW, Efird JT, Hedley-Whyte ET (1995) Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 147(1):114–123

    PubMed Central  CAS  PubMed  Google Scholar 

  46. Landau BJ, Kwaan HC, Verrusio EN, Brem SS (1994) Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res 54(4):1105–1108

    CAS  PubMed  Google Scholar 

  47. Gutova M, Najbauer J, Gevorgyan A et al (2007) Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One 2(2), e243

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  48. Hataji O, Taguchi O, Gabazza EC et al (2004) Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol 76(3):214–219

    Article  CAS  PubMed  Google Scholar 

  49. Pavey SJ, Hawson GA, Marsh NA (2001) Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis 12(1):51–58

    Article  CAS  PubMed  Google Scholar 

  50. Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K (1996) Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 78(3):487–492

    Article  CAS  PubMed  Google Scholar 

  51. Swiercz R, Wolfe JD, Zaher A, Jankun J (1998) Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin Cancer Res 4(4):869–877

    CAS  PubMed  Google Scholar 

  52. Shariat SF, Roehrborn CG, McConnell JD et al (2007) Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25(4):349–355

    Article  CAS  PubMed  Google Scholar 

  53. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S (1999) Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39(2):123–129

    Article  CAS  PubMed  Google Scholar 

  54. Hienert G, Kirchheimer JC, Pfluger H, Binder BR (1988) Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 140(6):1466–1469

    CAS  PubMed  Google Scholar 

  55. Kobayashi H, Fujishiro S, Terao T (1994) Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 54(24):6539–6548

    CAS  PubMed  Google Scholar 

  56. Kuhn W, Schmalfeldt B, Reuning U et al (1999) Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 79(11–12):1746–1751

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S (1998) Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res 58(10):2234–2239

    PubMed  Google Scholar 

  58. Hackel CG, Krueger S, Grote HJ et al (2000) Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma. Cancer 89(5):995–1003

    Article  CAS  PubMed  Google Scholar 

  59. Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T, Takagi H (1993) Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterol 88(11):1928–1933

    CAS  PubMed  Google Scholar 

  60. Cantero D, Friess H, Deflorin J et al (1997) Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 75(3):388–395

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Lescaille G, Menashi S, Cavelier-Balloy B et al (2012) EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression. BMC Cancer 12:115

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Keer HN, Gaylis FD, Kozlowski JM, Bauer KD, Sinha AA, Wilson MJ, Kwaan HC (1991) Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior. Prostate 18(3):201–214

    Article  CAS  PubMed  Google Scholar 

  63. Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM (1989) Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol 142(1):193–198

    CAS  PubMed  Google Scholar 

  64. Kirchheimer JC, Pfluger H, Ritschl P, Hienert G, Binder BR (1985) Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Invasion Metastasis 5(6):344–355

    CAS  PubMed  Google Scholar 

  65. Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J, Lund LR (1999) Cancer invasion and tissue remodeling–cooperation of protease systems and cell types. APMIS 107(1):120–127

    Article  CAS  PubMed  Google Scholar 

  66. Kwaan HC, Keer HN, Radosevich JA, Cajot JF, Ernst R (1991) Components of the plasminogen-plasmin system in human tumor cell lines. Semin Thromb Hemost 17(3):175–182

    Article  CAS  PubMed  Google Scholar 

  67. Duffy MJ, O’Grady P, Devaney D, O’Siorain L, Fennelly JJ, Lijnen HJ (1988) Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 62(3):531–533

    Article  CAS  PubMed  Google Scholar 

  68. Ossowski L, Russo-Payne H, Wilson EL (1991) Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 51(1):274–281

    CAS  PubMed  Google Scholar 

  69. Kobayashi H, Gotoh J, Shinohara H, Moniwa N, Terao T (1994) Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemost 71(4):474–480

    CAS  PubMed  Google Scholar 

  70. Yu HR, Schultz RM (1990) Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 50(23):7623–7633

    CAS  PubMed  Google Scholar 

  71. Wilhelm O, Schmitt M, Hohl S, Senekowitsch R, Graeff H (1995) Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 13(4):296–302

    Article  CAS  PubMed  Google Scholar 

  72. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, Kwaan HC (1995) Expresion of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in san athymic mouse model. J Clin Invest 96(6):2593–2600

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Pyke C, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Kirkeby L, Dano K (1994) Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 24(2):131–138

    Article  CAS  PubMed  Google Scholar 

  74. Bianchi E, Cohen RL, Thor AT, Todd RF 3rd, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS (1994) The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54(4):861–866

    CAS  PubMed  Google Scholar 

  75. de Vries TJ, Quax PH, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, van Muijen GN (1994) Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 144(1):70–81

    PubMed Central  PubMed  Google Scholar 

  76. Weidle UH, Wollisch E, Ronne E, Ploug M, Behrendt N, de Vries TJ, Quax PH, Verheijen JH, van Muijen GN, Ruiter DJ (1994) Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy. Ann Biol Clin 52(11):775–782

    CAS  Google Scholar 

  77. Pedersen H, Grondahl-Hansen J, Francis D et al (1994) Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54(1):120–123

    CAS  PubMed  Google Scholar 

  78. Bruckner A, Filderman AE, Kirchheimer JC, Binder BR, Remold HG (1992) Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1. Cancer Res 52(11):3043–3047

    CAS  PubMed  Google Scholar 

  79. Kariko K, Kuo A, Boyd D, Okada SS, Cines DB, Barnathan ES (1993) Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res 53(13):3109–3117

    CAS  PubMed  Google Scholar 

  80. Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312

    Article  CAS  PubMed  Google Scholar 

  81. Annecke K, Schmitt M, Euler U et al (2008) uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 45:31–45

    Article  CAS  PubMed  Google Scholar 

  82. Schmitt M, Harbeck N, Brunner N et al (2011) Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 11(6):617–634

    Article  CAS  PubMed  Google Scholar 

  83. Thomssen C (2012) First planned efficacy analysis of the NNBC 3-Europe trial: addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients. In: San Antonio breast cancer symposium, pp 1–1313

    Google Scholar 

  84. Jacobs VR, Kates RE, Kantelhardt E et al (2013) Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer. Breast Cancer Res Treat 138(3):839–850

    Article  CAS  PubMed  Google Scholar 

  85. Nienaber V, Wang J, Davidson D, Henkin J (2000) Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite. J Biol Chem 275(10):7239–7248

    Article  CAS  PubMed  Google Scholar 

  86. Jensen JK, Thompson LC, Bucci JC et al (2011) Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. J Biol Chem 286(34):29709–29717

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  87. Lin Z, Jiang L, Yuan C et al (2011) Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J Biol Chem 286(9):7027–7032

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  88. Xu X, Gardsvoll H, Yuan C, Lin L, Ploug M, Huang M (2012) Crystal structure of the urokinase receptor in a ligand-free form. J Mol biol 416(5):629–641

    Article  CAS  PubMed  Google Scholar 

  89. Huai Q, Mazar AP, Kuo A et al (2006) Structure of human urokinase plasminogen activator in complex with its receptor. Science 311(5761):656–659

    Article  CAS  PubMed  Google Scholar 

  90. Law RH, Caradoc-Davies T, Cowieson N et al (2012) The X-ray crystal structure of full-length human plasminogen. Cell Rep 1(3):185–190

    Article  CAS  PubMed  Google Scholar 

  91. Meyer JE, Brocks C, Graefe H et al (2008) The oral serine protease inhibitor WX-671 – first experience in patients with advanced head and neck carcinoma. Breast Care (Basel) 3(s2):20–24

    Google Scholar 

  92. Heinemann V, Ebert MP, Laubender RP, Bevan P, Mala C, Boeck S (2013) Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer 108(4):766–770

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  93. Goldstein LJ, Oliveria CT, Heinrich B et al (2012) A randomized double-blindphase II study of the combination of WX-671 plus capecitabine vs. capecitabine monothrapry in first-line HER-2 negaive metastatic breast cancer (MBC). In: CTRC-AACR San Antonio breast cancer symposium, 5-20-01

    Google Scholar 

  94. Kriegbaum MC, Persson M, Haldager L et al (2011) Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Curr Drug Targets 12(12):1711–1728

    Article  CAS  PubMed  Google Scholar 

  95. Wang F, Eric Knabe W, Li L et al (2012) Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor. Bioorg Med Chem 20(15):4760–4773

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  96. Gorantla B, Asuthkar S, Rao JS, Patel J, Gondi CS (2011) Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol Cancer Res 9(4):377–389

    Article  CAS  PubMed  Google Scholar 

  97. Gondi CS, Rao JS (2009) Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Methods Mol Biol 487:267–281

    PubMed Central  CAS  PubMed  Google Scholar 

  98. Van Buren G 2nd, Gray MJ, Dallas NA et al (2009) Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer 115(14):3360–3368

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  99. Rabbani SA, Ateeq B, Arakelian A et al (2010) An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia 12(10):778–788

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  100. Bauer TW, Liu W, Fan F et al (2005) Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 65(17):7775–7781

    CAS  PubMed  Google Scholar 

  101. Kenny HA, Leonhardt P, Ladanyi A et al (2011) Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res 17(3):459–471

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  102. Brooks TD, Wang SW, Brunner N, Charlton PA (2004) XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro. Anticancer Drugs 15(1):37–44

    Article  CAS  PubMed  Google Scholar 

  103. Binder BR, Mihaly J (2008) The plasminogen activator inhibitor “paradox” in cancer. Immunol Lett 118(2):116–124

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Feinberg School of Medicine, and the Robert H. Lurie Cancer, Northwestern University, Chicago, IL, USA

    Brandon J. McMahon MD & Hau C. Kwaan MD, FRCP

  2. Olson Pavilion, Room 8258, 710 N. Fairbanks Court, Chicago, IL, 60611, USA

    Brandon J. McMahon MD & Hau C. Kwaan MD, FRCP

Authors
  1. Brandon J. McMahon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hau C. Kwaan MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hau C. Kwaan MD, FRCP .

Editor information

Editors and Affiliations

  1. Institute of Biochemistry and Clinical B, Catholic University School of Medicine, Rome, Italy

    Roberto Scatena

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

McMahon, B.J., Kwaan, H.C. (2015). Components of the Plasminogen-Plasmin System as Biologic Markers for Cancer. In: Scatena, R. (eds) Advances in Cancer Biomarkers. Advances in Experimental Medicine and Biology, vol 867. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7215-0_10

Download citation

Publish with us

Policies and ethics

Search

Navigation